Standard BioTools Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 99/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.55.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Standard BioTools Inc's Score
Industry at a Glance
Industry Ranking
99 / 207
Overall Ranking
249 / 4563
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
1.550
Target Price
+6.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Standard BioTools Inc Highlights
StrengthsRisks
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 78.09% year-on-year.
Undervalued
The company’s latest PE is -4.12, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 277.96M shares, decreasing 8.99% quarter-over-quarter.
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Ticker SymbolLAB
CompanyStandard BioTools Inc
CEOEgholm (Michael)
Websitehttps://www.standardbio.com/
FAQs
What is the current price of Standard BioTools Inc (LAB)?
The current price of Standard BioTools Inc (LAB) is 1.380.
What is the symbol of Standard BioTools Inc?
The ticker symbol of Standard BioTools Inc is LAB.
What is the 52-week high of Standard BioTools Inc?
The 52-week high of Standard BioTools Inc is 2.140.
What is the 52-week low of Standard BioTools Inc?
The 52-week low of Standard BioTools Inc is 0.920.
What is the market capitalization of Standard BioTools Inc?
The market capitalization of Standard BioTools Inc is 529.39M.
What is the net income of Standard BioTools Inc?
The net income of Standard BioTools Inc is -184.90M.
Is Standard BioTools Inc (LAB) currently rated as Buy, Hold, or Sell?
According to analysts, Standard BioTools Inc (LAB) has an overall rating of Buy, with a price target of 1.550.
What is the Earnings Per Share (EPS TTM) of Standard BioTools Inc (LAB)?
The Earnings Per Share (EPS TTM) of Standard BioTools Inc (LAB) is -0.335.